David A. Siegel Halozyme Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 5,900 shares of HALO stock, worth $382,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,900Holding current value
$382,556% of portfolio
0.0%Shares
26 transactions
Others Institutions Holding HALO
# of Institutions
549Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.14 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$861 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$466 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$270 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$224 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.03B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...